Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 20/20 | 1.00 |
| ▸ | KCNK9 | Q9NPC2 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29791127 | 1.00 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29791113 | 0.92 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20291857 | 0.92 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432744 | 0.90 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20291855 | 0.90 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL20291863 | 0.90 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL29432806 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963281 | 0.87 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963279 | 0.86 | KCNK3 (1.00) | KCNK3KCNK9 | |
| SCHEMBL18963169 | 0.84 | KCNK3 (1.00) | KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-09-01 | — | — | US | disclosed |
| EP-3386979-B1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF THE TASK-1 AND TASK-2 CHANNELS FOR TREATING SLEEP-RELATED BREATHING DISORDERS | Bayer Pharma AG (DE) | 2020-07-29 | — | — | EP | disclosed |
| EP-3386979-B1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF THE TASK-1 AND TASK-2 CHANNELS FOR TREATING SLEEP-RELATED BREATHING DISORDERS | Bayer Pharma AG (DE) | 2020-07-29 | — | — | EP | disclosed |
| US-20200093737-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-26 | — | — | US | disclosed |
| US-20200085734-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-I AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-03-19 | — | — | US | disclosed |
| EP-3558380-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| EP-3558379-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | Bayer Pharma Aktiengesellschaft (DE) | 2019-10-30 | — | — | EP | disclosed |
| WO-2018114501-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| WO-2018114503-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-06-28 | — | — | WO | disclosed |
| EP-3338803-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING INHIBITORS FOR TASK-1 AND TASK-3 CHANNELS AND THEIR USE IN THERAPY OF RESPIRATORY DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-27 | — | — | EP | disclosed |
| EP-3338764-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING INHIBITORS FOR TASK-1 AND TASK-3 CHANNELS AND THEIR USE IN THERAPY OF RESPIRATORY DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2018-06-27 | — | — | EP | disclosed |
| WO-2017097792-A1 | 2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | KCNK3 172/4885KCNK9 685/4885 |
| US-20200085734-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-I AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | CACNA1I, CACNA1G, CACNA1H | KCNK3 61/4885KCNK9 299/4885 |
| US-20200093737-A1 | PHARMACEUTICAL DOSAGE FORMS CONTAINING TASK-1 AND TASK-3 CHANNEL INHIBITORS, AND THE USE OF SAME IN BREATHING DISORDER THERAPY | CACNA1I, CACNA1G, CACNA1D | KCNK3 58/4885KCNK9 298/4885 |
| US-10759794-B2 | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders | TRPV2, CACNA1G, KCNJ2 | KCNK3 85/4885KCNK9 204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.